Insmed Surges, Market Cap Increases by 2 Trillion Won in One Day

Nasdaq-listed biotech Insm…ed Inc. (NASDAQ: INSM) surged 6.9% in U.S. trading on June 11, closing at $98.20—roughly ₩130,000.

Its market capitalization rose by about $1.6 billion (≈₩2 trillion) from the previous day to approximately $21.3 billion (≈₩27 trillion).

Trading volume reached 3.84 million shares, signaling concentrated short-term buying interest.

A report from the prior session noted heavy call-option activity in Insm…ed, suggesting a strong influx of bullish bets in the derivatives market.

In its May release of first-quarter results, the company posted revenue of $306 million and a net loss per share of $0.76, both exceeding Wall Street consensus and underscoring the sales momentum of its lead asset, brensocatib.

Insm…ed is a U.S. biopharmaceutical firm focused on developing and commercializing treatments for rare and severe pulmonary diseases. Its core pipeline includes the inhaled antibiotic Arikayce and brensocatib (brand name Brensufrip), a therapy for non-cystic fibrosis bronchiectasis.

Brensocatib is the first—and currently the only—treatment for this condition approved by both the European Union and the U.S. Food and Drug Administration. Future expansions of approved indications and the pace of its global rollout are viewed as critical determinants of the company’s valuation.